Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 7/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 7/20 | 0.41 |
| ▸ | THRB | P10828 | 4/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18883237 | 0.73 | MAP3K14 (0.81) | MAP3K14 | |
| SCHEMBL16532275 | 0.73 | MAP3K14 (1.00) | MAP3K14 | |
| SCHEMBL16517638 | 0.71 | MAP3K14 (1.00) | MAP3K14 | |
| SCHEMBL18673438 | 0.70 | MAP3K14 (0.57) | MAP3K14 | |
| SCHEMBL18673437 | 0.70 | MAP3K14 (0.57) | MAP3K14 | |
| SCHEMBL16516618 | 0.69 | GAA (0.56) | MAP3K14GAATP53THRBRORC | |
| SCHEMBL18673379 | 0.67 | MAP3K14 (0.58) | MAP3K14 | |
| SCHEMBL18673403 | 0.64 | MAP3K14 (0.60) | MAP3K14RORC | |
| SCHEMBL15247925 | 0.64 | CNR2 (0.61) | MAP3K14GAATP53THRBLMNA | |
| SCHEMBL16516815 | 0.62 | GAA (0.57) | MAP3K14GAATP53THRBRORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170145034-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | GENENTECH, INC. (US) | 2017-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170145034-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | NFKB2, NFKB1, RELA | MAP3K14 514/4885GAA 1695/4885TP53 2153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.